Schleifer Leonard S's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Apr 4, 2022
- Accession no.
- 0001883850-22-000036
- Filed
- Apr 4, 2022
- Trade date
- Mar 31, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $2.05M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schleifer Leonard SCIK 0001218629 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Stock | SSaleDisposed | −2,886 | $710.01F2 | −$2,049,088.86 | 18,292 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents volume-weighted average price of sales of 2,886 shares of Company stock on March 31, 2022 at prices ranging from $710.00 to $710.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 31, 2022 at each separate price.
Referenced by the price of 1 transaction in Table I.